About Shanghai Yizhong Pharmaceutical Company

The company was founded in September 2009 by 6 natural persons including Li Duan. The company limited was changed as a company limited by shares using November 30, 2019 as the reference date for stock reform. As an enterprise mainly engaged in the development of new dosage forms of anti-tumor drugs and related products, the company mainly develops, produces and sells the new anti-tumor drug “paclitaxel polymer micelle for injection”. The company's core product “injectable paclitaxel polymer micelle”. Corporate honors: It has successively won many honors such as the free funding project of the National Science and Technology SME Innovation Fund and the Shanghai Science and Technology Commission's scientific and technological achievement transformation and industrialization project. Clinical studies on non-small cell lung cancer have shown that the objective remission rate (ORR) and progression-free survival (PFS) of micellar tumor treatment with paclitaxel have obvious clinical advantages over other paclitaxel dosage forms that have already been marketed. Honors include the Shanghai Science and Technology Commission's “Science and Technology Enterprise Cultivation Project”; the Shanghai Science and Technology Commission's “Research Plan Project”; the Ministry of Science and Technology Center Enterprise Technology Innovation Fund Management Center's “Science and Technology SME Technology Innovation Project”; and the “Special Development Fund Key Project” of the Shanghai Zhangjiang State-funded Innovation Demonstration Zone.